The National Engineering Research Center of Diagnostic Reagents and Vaccines for Infectious Diseases of Xiamen University was established with the approval of the Ministry of Science and Technology in 2005. In 2009, it passed the acceptance of the Ministry of Science and Technology with "excellent" status, and 20 1 1 was awarded "Excellent Team for Implementing the Eleventh Five-Year National Science and Technology Plan" by the Ministry of Science and Technology. The center has long been engaged in the research and development of vaccines and diagnostic reagents, as well as basic and applied research related to virus molecular biology, genetic engineering, immunology and cell biology. At present, the center has 3,000 square meters of special laboratories and more than 35 million yuan of special instruments and equipment. Established mature key technology platforms such as genetic engineering, monoclonal antibody, cell model, experimental animals, protein structure, bioinformatics workstation and diagnostic technology. Now it has developed into a young and capable scientific research team, a relatively perfect technical platform and a modern bioengineering laboratory with infrastructure. In 2009, the center was selected as a national-level international scientific and technological cooperation and exchange base and a national-level scientific and technological cooperation and exchange base with Taiwan, and served as the chairman of the National Strategic Alliance for Technological Innovation of Infectious Disease Diagnostic Reagent Industry.

In the past five years, the center has successively undertaken 13 national key scientific research projects, including major projects of the National 863 Program, major national science and technology projects, major national support programs and major international science and technology cooperation projects, with an average annual research funding of more than 20 million yuan. Won various scientific and technological awards 15, including the second prize of national technological invention (20 10) and the second prize of national scientific and technological progress (200 1). He has published more than 160 research papers in SCI journals, such as PNAS, The Lancet and Pathogens in Public Library of Science. Apply for 30 invention patents (including international patents 13), and have been granted patents 10; Obtained new drug certificate/registration number 17, including 3 national key new product certificates and 3 EU CE certified products, which have been industrialized and widely used in many clinical units in China. Recombinant hepatitis E vaccine, a national first-class new drug with many core independent intellectual property rights, is the first vaccine of its kind to complete phase III clinical trials at home and abroad, and was rated as one of the top ten medical achievements in China in 20 10. Recombinant human papillomavirus 16/ 18 bivalent vaccine (cervical cancer vaccine) is the third preventive cervical cancer vaccine in the world.

At present, the center has formed its own characteristics in the research of infectious disease diagnostic reagents and vaccines, and has become one of the leading laboratories in this field in China, especially in the originality of scientific research results and the conversion rate, speed, scale and market share of products.